MLN0128

DRUG10 trials

Sponsors

Millennium Pharmaceuticals, Inc., Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Kathy Miller, University of Colorado, Denver

Conditions

Advanced Nonhematologic MalignanciesAdvanced Solid MalignanciesAnaplastic Thyroid CancerClear-cell Metastatic Renal Cell CarcinomaDifferentiated Thyroid CancerHCCHematologic MalignanciesHepatocellular Carcinoma

Phase 1

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

CompletedNCT01058707

Millennium Pharmaceuticals, Inc.Advanced Solid Malignancies

Start: 2010-01-04End: 2019-02-07Updated: 2020-04-01

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

CompletedNCT01118689

Millennium Pharmaceuticals, Inc.Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Waldenstrom Macroglobulinemia

Start: 2010-11-30End: 2013-07-31Updated: 2013-08-02

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

CompletedNCT01351350

Millennium Pharmaceuticals, Inc.Advanced Solid Malignancies, Hematologic Malignancies

Start: 2011-02-28End: 2017-09-15Updated: 2019-08-08

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

CompletedNCT02244463

Dana-Farber Cancer InstituteAnaplastic Thyroid Cancer, Differentiated Thyroid Cancer, Thyroid Cancer

Start: 2015-07-31End: 2022-04-28Updated: 2024-01-12

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

CompletedNCT02327169

Millennium Pharmaceuticals, Inc.Advanced Nonhematologic Malignancies

Start: 2015-01-14End: 2018-07-02Updated: 2020-02-25

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

CompletedNCT02514824

Dana-Farber Cancer InstituteMerkel Cell Carcinoma

Start: 2015-10-31End: 2017-06-30Updated: 2020-12-29

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

TerminatedNCT02575339

Kathy MillerHCC, Hepatocellular Carcinoma, Liver Cancer

Start: 2016-07-18End: 2020-11-24Updated: 2022-07-26

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

CompletedNCT02719691

University of Colorado, DenverMetastatic Breast Cancer, Solid Tumors

Start: 2016-05-13End: 2020-03-18Updated: 2022-07-25

Phase 2

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

CompletedNCT02091531

Memorial Sloan Kettering Cancer CenterMetastatic Castration-Resistant Prostate Cancer

Start: 2014-03-31End: 2018-10-31Updated: 2019-11-21

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

CompletedNCT02724020

Millennium Pharmaceuticals, Inc.Clear-cell Metastatic Renal Cell Carcinoma

Start: 2016-06-30End: 2020-10-13Updated: 2021-11-19

Related Papers

A phase Ib study of the combination of alisertib (Aurora A kinase inhibitor) and MLN0128 (dual TORC1/2 Inhibitor) in patients with advanced solid tumors, final expansion cohort data.

Journal of Clinical Oncology2022-06-013 citations

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.

2021-11-297 citations

Precision medicine in aggressive thyroid cancer: Moving beyond multitargeted tyrosine kinase inhibitors

Cancer Cytopathology2021-11-083 citations

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.

2020-09-1170 citations

Abstract P3-02-04: Combined aurora kinase A and mTORC 1/2 inhibition results in disruption of tumor cell energetics in triple negative breast cancer

Cancer Research2020-02-15

Abstract B175: Rational combination of mTOR and Aurora kinase A inhibition in preclinical models of triple-negative breast cancer

Molecular Cancer Therapeutics2018-01-01

TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.

2017-06-1039 citations

A Phase II Study of the Dual mTOR Inhibitor MLN0128 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Journal of Clinical Oncology2016-05-203 citations

A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2015-05-201 citations

Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies.

Molecular Cancer Therapeutics2013-11-0119 citations

Abstract B189: MLN0128, an investigational mTORC1/2 inhibitor, demonstrates potent antitumor activity alone and in combination with paclitaxel in preclinical models of endometrial cancer.

Molecular Cancer Therapeutics2013-11-012 citations